NCT00917904CompletedPhase 1
A Double-blind, Randomized, Placebo-Controlled Phase I/II Study to Evaluate the Safety and Acceptability of Dapivirine Gel 4789, 0.05%, 2.5g, a Vaginal Microbicide, Conducted Using Daily Monitored Adherence in Healthy, HIV-Negative Women.
International Partnership for Microbicides, Inc.3 sites in 1 country100 target enrollmentStarted: July 2009Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Enrollment
- 100
- Locations
- 3
- Primary Endpoint
- Gynaecological examinations, including pelvic/speculum examination and colposcopy, and laboratory STI testing.
Study Overview
Brief Summary
The purpose of this study is to determine whether dapivirine gel 4789 is safe for daily use by healthy women in South Africa.
Detailed Description
To reduce the influence of adherence as a factor in the interpretation of efficacy results, IPM is considering using a DOT (Directly Observed Therapy) based method for vaginal microbicide gel delivery in a future Phase III study. IPM has denoted this DOT based method as Daily Monitored Adherence (DMA). IPM014B is a Phase I/II study designed: (1) to assess and compare the safety of a once daily application of Dapivirine Gel 4789, 0.05% 2.5g and a matching vehicle placebo gel; (2) to assess the acceptability of a once daily application of Dapivirine gel 4789, 0.05% 2.5g and a matching vehicle placebo gel; and (3) to assess the feasibility of utilizing the DMA method for a large-scale phase III efficacy study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 40 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Women 18 to 40 years of age inclusive who can give written informed consent
- •Available for all visits and consent to follow all procedures scheduled for the study
- •Agree to daily application of gel and monitoring as per Daily Monitored Adherence (DMA) method
- •Healthy and self-reported sexually active
- •HIV-negative as determined by a HIV rapid test at time of enrollment
- •On a stable form of contraception and willing to continue on this stable method of contraception, OR, Have undergone surgical sterilisation at least 3 months prior to enrollment
- •In the absence of the use of exogenous hormone(s), have a self-reported regular menstrual cycle defined as having a minimum of 21 days and a maximum of 36 days between menses
- •Upon pelvic/speculum examination and colposcopy at the time of enrollment, the cervix and vagina appear normal as determined by the investigator
- •Asymptomatic for genital infections at the time of enrollment
- •Willing to refrain from use of vaginal products or objects within 14 days prior to enrollment and for the duration of the study
- •Willing to answer acceptability and adherence questionnaires throughout the study
- •Willing to refrain from participation in any other research study for the duration of this study
- •Willing to provide adequate locator information for study retention purposes and be reachable per local standard procedures
Exclusion Criteria
- •Currently pregnant or last pregnancy outcome within 3 months prior to enrolment
- •Currently breast-feeding
- •Participated in any other research study within 60 days prior to screening
- •Previously participated in any HIV vaccine study
- •Untreated urogenital infections (either symptomatic or asymptomatic) within 2 weeks prior to enrollment
- •Presence of abnormal physical finding on the vulva, vaginal walls or cervix during pelvic/speculum examination and/or colposcopy
- •History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction
- •Pap smear result at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation
- •Any Grade 2, 3 or 4 baseline haematology, chemistry or urinalysis laboratory abnormality according to the DAIDS Table for Grading Adverse Experiences
- •Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynaecologic surgery within 90 days prior to enrollment
- •Any history of anaphylaxis or severe allergy resulting in angioedema; or a history of sensitivity/allergy to latex
- •Any serious acute, chronic or progressive disease
- •Any condition(s) that, in the opinion of the investigator, might interfere with adherence to study requirements or evaluation of the study objectives
Arms & Interventions
vehicle placebo gel
Placebo Comparator
Intervention: placebo (Drug)
dapivirine gel
Experimental
Intervention: dapivirine (Drug)
Outcomes
Primary Outcomes
Gynaecological examinations, including pelvic/speculum examination and colposcopy, and laboratory STI testing.
Time Frame: Week 0, 1, 2, 4, 6 & 10
Safety laboratory tests
Time Frame: enrollment & last day of gel use
Adverse event/serious adverse event reports
Time Frame: throughout study
Secondary Outcomes
- Questionnaires concerning acceptability and adherence to daily use of vaginal gel.(Week 0, 2, 6 & 10)
- Documentation of adherence to the DMA method including the Applicator Collection Checklist, focus groups and male interviews.(throughout study)
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 1
An Expanded Safety Study of Dapivirine Gel 4759 in AfricaAcquired Immunodeficiency SyndromeHIV InfectionsNCT00917891International Partnership for Microbicides, Inc.280
Completed
Phase 1
Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative AdultsHIV InfectionsNCT03239483National Institute of Allergy and Infectious Diseases (NIAID)28
Completed
Phase 1
A Safety Study of Two Dapivirine (TMC120) Vaginal Gels in the United StatesHIV-1 InfectionsNCT00799058International Partnership for Microbicides, Inc.128
Completed
Phase 1
Assessing the Safety of Dapivirine Gel and Film FormulationsHIV InfectionsNCT01548560International Partnership for Microbicides, Inc.60
Completed
Phase 2
A Study of Deuremidevir Hydrobromide for Suspension in Chinese Infants Hospitalized With RSVRespiratory Syncytial Virus InfectionNCT06206720Vigonvita Life Sciences60